Heat Biologics, Inc. (NASDAQ:HTBX) share price increased to $0.97 each in the last business day compared to a prior close of $0.9. The current price is 6.11% above its 20-day SMA and -11.67% below its 50-day SMA. The shares have fallen -5.82% over the trailing 3 months.

Heat Biologics, Inc. (NASDAQ:HTBX) on March 13, 2017 announced that the company achieved the efficacy endpoint for its Phase 1b trial evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®), for the treatment of non-small cell lung cancer (NSCLC) and that the trial met the expansion criteria to advance into a Phase 2.  In reviewing the Phase 1b data, the Data Monitoring Committee (DMC) determined that the Phase 1b safety endpoint was met and that there do not appear to be additional toxicities seen in the HS-110/nivolumab combination compared to existing data on nivolumab alone.  Furthermore, 5 out of 15 patients treated with the HS-110/nivolumab combination had 20% or greater tumor reduction.  The DMC concluded that the positive safety profile, mechanistic evidence and encouraging signs of synergistic efficacy warranted expansion to a Phase 2 trial.

Gilead Sciences, Inc. (NASDAQ:GILD) shares closed at $68.1, down -0.09 points or -0.13 percent from  the previous close price. The up to date insider trading filings show Executive Chairman MARTIN JOHN C has disposed of 73,333 shares,reducing the ownership to 3,126,636 units. The transaction occurred on Mar 01, 2017, at $70.38 per share worth a total $5,161,180. There was another major transaction on the insider-trading front. WILSON GAYLE E, Director at GILD bought 20,365 common shares at a per share price of $69.3 to hold 120,471 shares. The stock recently traded at a volume of 0 shares vs. an average volume of 10.77M. The latest closing price is now lower -4.83% for the past quarter. The price is now -4.29% below its 50-day moving average and -10.97% below its 200-day moving average. The percentage change return over the last fifty two weeks remained -22.28%. The price range in the same period had a highest hit of $103.1 while lowest level in that period was $65.38.

Gilead Sciences, Inc. (NASDAQ:GILD) on February 28, 2017 announced that John F. Milligan, PhD, Gilead’s President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference in Miami on Tuesday, March 14 at 9:00 a.m. Eastern Time. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.